When Alexander Fleming inadvertently discovered penicillin in 1928, the world assumed that the age-old scourge of infectious diseases was about to end. For decades, newly synthesized antibiotics arrested killers such as tuberculosis and syphilis, while cutting-edge antivirals saved millions of people from polio and smallpox.
Sadly, infectious diseases remain a deadly force worldwide. Bacteria develop resistance to antibiotics, often faster than new drugs can be created. New viruses continue to emerge, from HIV to SARS to endless mutations of influenza. In undeveloped countries, people still face deadly threats such as malaria and measles.
MPI Research joins forces with pharmaceutical and biotechnology Sponsors in the race to develop new vaccines, antibacterials, and antivirals. Our technical capabilities, scientific accuracy, and depth of experience set the pace for research in infectious diseases.
MPI Research has the tools and expertise by bringing an essential element to its work with Sponsors. Our Biosafety Level Two barrier facilities are available to deliver results under high regulatory standards and at a competitive price.
- Bacterial peritonitis/septicemia (MRSA, Streptococcus pneumoniae)
- Acute bacterial otitis media (Haemophilus influenzae)
- Otitis externa (Pseudomonas aeruginosa)
- Vaccine safety studies (rodents, ferret, dog)
- Biosafety level (BSL)-2 laboratory and vivarium space
- Bacterial enumeration in tissues and organs
- Inoculation routes, including intratracheal, nasal, and intramuscular options
- Frozen bacterial stocks and ATCC availability
- Antigen-specific responses (titering, isotyping)
- T helper cell (Th1/Th2) ex vivo analysis
Studies performed in the past 2 years